Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7720MR)

This product GTTS-WQ7720MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7720MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14744MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ2151MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ4195MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ12956MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ8163MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ15175MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ14532MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ7812MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW